834.55

0.17% 1.39

After Hours: 834.36 -0.19 -0.02%

Argen X Se Adr (ARGX)

Overview News Price History Option Chain Why ARGX Down? Discussions Forecast

Argen X Se Adr stock is traded at $834.55, with a volume of 197.03K. It is up +0.17% in the last 24 hours and up +5.84% over the past month. Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Previous Close:

$833.16

Open:

$832.15

24h Volume:

197.03K

Relative Volume:

0.56

Market Cap:

$51.64B

Revenue:

$3.06B

Net Income/Loss:

$1.28B

P/E Ratio:

42.42

EPS:

19.6719

Net Cash Flow:

$447.35M

1W Performance:

-1.92%

1M Performance:

+5.84%

6M Performance:

+30.62%

1Y Performance:

+31.21%

1-Day Range:

$822.60

$837.54

1-Week Range:

$810.74

$861.73

52-Week Range:

$510.06

$934.62

Argen X Se Adr Stock (ARGX) Company Profile

Name

Argen X Se Adr

Sector

Healthcare (1108)

Industry

Biotechnology (619)

Phone

Address

Employee

1,639

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

ARGX's Discussions on Twitter

Compare ARGX vs VRTX, REGN, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARGX Argen X Se Adr	834.55	51.56B	3.06B	1.28B	447.35M	19.67
VRTX Vertex Pharmaceuticals Inc	461.24	117.59B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	778.97	79.81B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	322.28	42.67B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	351.27	39.11B	4.98B	69.60M	525.67M	0.5198

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-24-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-15-25	Resumed	Truist	Buy
Sep-11-25	Downgrade	Deutsche Bank	Buy → Hold
Aug-25-25	Initiated	RBC Capital Mkts	Outperform
Jul-08-25	Upgrade	Deutsche Bank	Hold → Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight
May-13-25	Upgrade	Robert W. Baird	Neutral → Outperform
Mar-17-25	Upgrade	Bernstein	Mkt Perform → Outperform
Mar-12-25	Upgrade	Deutsche Bank	Sell → Hold
Jan-17-25	Downgrade	Deutsche Bank	Hold → Sell
Nov-12-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Nov-05-24	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Nov-01-24	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-24	Upgrade	William Blair	Mkt Perform → Outperform
Oct-10-24	Resumed	Raymond James	Strong Buy
Oct-04-24	Downgrade	Deutsche Bank	Buy → Hold
Aug-06-24	Upgrade	Barclays	Equal Weight → Overweight
Jul-25-24	Upgrade	Deutsche Bank	Hold → Buy
Jul-23-24	Upgrade	Oppenheimer	Perform → Outperform
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-20-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jul-31-23	Initiated	Scotiabank	Sector Perform
Jul-24-23	Downgrade	UBS	Buy → Neutral
Jul-17-23	Resumed	Evercore ISI	Outperform
Jun-15-23	Initiated	Societe Generale	Sell
May-31-23	Initiated	UBS	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-14-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-07-22	Initiated	William Blair	Outperform
Oct-12-22	Initiated	Oppenheimer	Perform
Jul-29-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-22	Resumed	Stifel	Buy
May-03-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-29-21	Upgrade	Piper Sandler	Neutral → Overweight
Oct-29-21	Upgrade	Guggenheim	Neutral → Buy
Oct-28-21	Upgrade	Raymond James	Outperform → Strong Buy
Oct-07-21	Initiated	Jefferies	Buy
Sep-23-21	Upgrade	Redburn	Neutral → Buy
Sep-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-23-21	Initiated	Deutsche Bank	Hold
Jul-19-21	Resumed	Wolfe Research	Outperform
Jun-18-21	Initiated	UBS	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-23-21	Initiated	Redburn	Neutral
Mar-05-21	Reiterated	H.C. Wainwright	Neutral
Feb-02-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-04-21	Downgrade	Guggenheim	Buy → Neutral
Aug-25-20	Initiated	Raymond James	Outperform
Aug-19-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-20	Initiated	H.C. Wainwright	Neutral
Feb-10-20	Initiated	BofA/Merrill	Buy
Nov-05-19	Initiated	Credit Suisse	Neutral
Oct-31-19	Upgrade	William Blair	Mkt Perform → Outperform
Oct-22-19	Initiated	JP Morgan	Overweight
Sep-27-19	Initiated	Wells Fargo	Market Perform
Sep-16-19	Resumed	Cowen	Outperform
Jun-28-19	Initiated	Robert W. Baird	Outperform
Jan-18-19	Resumed	SunTrust	Buy
Jan-04-19	Initiated	Morgan Stanley	Overweight
Dec-17-18	Initiated	Goldman	Buy
Dec-14-18	Initiated	Wolfe Research	Outperform
Jun-29-18	Initiated	Nomura	Buy
Apr-09-18	Initiated	SunTrust	Buy
Jan-29-18	Reiterated	JMP Securities	Mkt Outperform

View All

Argen X Se Adr Stock (ARGX) Latest News

Feb 06, 2026

Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4 - Insider Monkey

Feb 06, 2026

Feb 03, 2026

Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth - Finviz

Feb 03, 2026

Jan 31, 2026

Wells Fargo analyst sees potential in Argenx SE’s (ARGX) Vyvgart, increases PT to $1,317 - MSN

Jan 31, 2026

Goldman Sachs Assumes Penguin Solutions (PENG) Coverage with Buy Rating, $25 PT - Yahoo Finance

Jan 31, 2026